Jefferies keeps Amgen at hold

Amgen, Inc. was given a hold rating and a $76 price target by Jefferies & Co., Inc. analyst Adam Walsh. The company announced a delay in the CERA filing for an oncology medication to 2009, from the original expectation of 2007. Amgen cited longer than expected time to execute the oncology trials as reason for the delay. Shares of the Thousand Oaks, Calif., biotechnology company were up $3.30, or 4.53%, at $6.19 on volume of 34,443,202 shares versus the three-month running average of 7,992,620 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.